| |
Average time between biopsies (days)
|
722 [621–821]
|
|
Average TMB difference (mutations/Mb)
|
0.583 [− 0.900–2.064]
|
|
Age at first biopsy (years)
|
57.36 [55.22–59.50]
|
|
Gender
|
Men
|
106 (52.48%)
|
|
Women
|
96 (47.52%)
|
|
Diagnoses
|
Colorectal adenocarcinoma
|
29 (14.36%)
|
|
Lung adenocarcinoma
|
20 (9.901%)
|
|
Breast invasive ductal adenocarcinoma
|
10 (4.950%)
|
|
Metastatic (any primary)
|
99 (49.00%)
|
|
Biopsy sites
|
First biopsy
|
Last biopsy
|
|
Lung
|
22 (10.89%)
|
Liver
|
33 (16.34%)
|
|
Colon
|
19 (9.406%)
|
Lung
|
20 (9.901%)
|
|
Soft Tissue
|
16 (7.921%)
|
Lymph Node
|
16 (7.921%)
|
|
Bone Marrow
|
11 (5.446%)
|
Bone Marrow
|
14 (6.931%)
|
|
Liver
|
11 (5.446%)
|
Colon
|
12 (5.941%)
|
|
Others
|
123 (60.89%)
|
Others
|
107 (52.97%)
|
|
Immunotherapy (checkpoint)
|
Number receiving immunotherapy between biopsies
|
55 (27.23%)
|
|
Number NOT receiving immunotherapy
|
147 (72.77%)
|
|
TMB measured
|
High at first biopsy (≥ 20 mutations/Mb)
|
10 (4.950%)
|
|
Intermediate at first biopsy (5 < TMB ≤ 19 mutations/Mb)
|
49 (24.26%)
|
|
Low at first biopsy (≤ 5 mutations/Mb)
|
143 (70.79%)
|
|
High at second biopsy (≥ 20 mutations/Mb)
|
13 (6.436%)
|
|
Intermediate at second biopsy (5 < TMB ≤ 19 mutations/Mb)
|
50 (24.75%)
|
|
Low at second biopsy (≤ 5 mutations/Mb)
|
139 (68.81%)
|
